Clazosentan

Research use only, not for human use.

Clazosentan (Ro 61-1790) is a selective antagonist of the endothelin A receptor (ETAreceptor) that inhibits ET-1-mediated vasoconstriction, preventing cerebral vasospasm and vasospasm-associated cerebral infarction.

Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.

Clazosentan (0.1 μM) inhibits the ETA receptor in cerebral arteries.Clazosentan is a substrate of the organic anion-transporting polypeptide (OATP) 1B1/1B3.

Clazosentan (10 μM, 0.05?mL/kg, intracisternal injection) inhibits the contractile responses to ET-1 in rats.Clazosentan (10 mg/kg, s.c.) inhibits IL-33-induced hypernociception in mice.Animal Model:RatsDosage:10 μM, 0.05?mL/kg Administration: Intracisternal injection Result:Inhibited the contractile responses to ET-1, without preventing SAH-induced upregulation of ET receptors in cerebral arteries.

——

GPCR/G Protein

Endothelin Receptor

Endothelin Receptor

——

——

180384-56-9

577.57

C25H23N9O6S

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (144.28 mM; Ultrasonic )

COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OCCO)-c1ccnc(c1)-c1nn[nH]n1

——

(-20℃)

With Ice Pack

≥ 2 years